Ann: Invitation to Investor Briefing, page-14

I see this early May
First patient treated in landmark Alzheimer’s disease clinical trial
• Actinogen Medical reaches a major milestone with the first patient enrolled into XanADu – its Phase II clinical trial of Xanamem™ in Alzheimer’s disease. •
The first trial patient was treated at the Central Coast Neurosciences Research site in New South Wales, Australia. •
This marks a defining moment in the development of Xanamem following more than a decade of research. • Xanamem blocks excess production of cortisol, the stress hormone, in the brain and represents a promising new approach to treat Alzheimer’s disease •
XanADu will enrol 174 patients at 20 research sites in the USA, the UK and Australia with the final patient expected in Q4 2018 and top-line results in Q1 2019 Sydney, 16 May 2017: Actinogen Medical (ASX: ACW) is delighted to announce the treatment of the first patient in XanADu, its Phase II clinical trial of Xanamem in Alzheimer’s disease.
This is the first patient to be enrolled into XanADu globally, and represents a significant milestone following more than a decade of research undertaken by Edinburgh University in Scotland and Actinogen Medical in Australia, to develop Xanamem as a promising new treatment for Alzheimer’s disease.
The first patient was treated at the Central Coast Neurosciences Resea